NCT02421094已完成2 期
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS)
研究概览
简要总结
A Randomized, Controlled, Double-blind, Parallel Group, Single Center Phase 2 Clinical Trial to Evaluate Multiple Non-Invasive Liver Fibrosis Imaging Methods in the Assessment of the Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis in Patients with NASH with Advanced Fibrosis
详细描述
The primary objective is to determine the difference between placebo and GR-MD-02 treatment in the baseline adjusted mean change in liver fibrosis as measured by corrected T1 (cT1) mapping as determined from LiverMultiScan (LMS), a multi-parametric MRI protocol.
Secondary objectives include evaluating differences between subjects treated with GR-MD-02 versus placebo in:
- The baseline-adjusted change in liver stiffness as measured by MR-elastography
- The baseline-adjusted change in liver stiffness as measured by FibroScan® scores.
An exploratory objective will be to evaluate the correlation of the three diagnostic modalities of LiverMultiScan, MR-Elastography, and FibroScan®.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have liver biopsy demonstrating NASH with Brunt Stage 3 fibrosis within 12 months of randomization. The subject is ≥ 18 years of age and ≤ 75 years old at the time of screening
- •The subject is willing and able to provide written informed consent
- •The subject is not pregnant and must have a negative pregnancy test prior to start of the study. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-child-bearing potential.
- •Fertile men and women participating in heterosexual relations must agree to use effective means of contraception throughout their participation in this study and for 90 days after discontinuation of study medication.
- •Lactating females must agree to discontinue nursing before the start of study treatment and refrain from nursing until 90 days after discontinuation of study medication.
- •Male subjects must refrain from sperm donation throughout the study period and for a period of 90 days following the last dose of study drug.
排除标准
- •A history of hepatic decompensation including any episode of variceal bleeding, clinically detectable ascites, or overt hepatic encephalopathy.
- •Status post TIPS (Transjugular Intrahepatic Porto-systemic Shunt) procedure.
- •Evidence of other forms of chronic liver disease including viral hepatitis B or C, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alpha-1 antitrypsin deficiency, alcoholic hepatitis, hemochromatosis, liver cancer, or history of biliary diversion.
- •Any of the following laboratory values: Serum alanine aminotransferase (ALT) and aspartate aminotransferase levels > 10X upper limits of normal, Serum creatinine ≥ 2.0 mg/dL, Platelet count < 60,000/mm3, Serum albumin ≤ 2.8 g/dL, INR ≥ 1.7, Direct bilirubin ≥ 2.0 mg/dL
- •A MELD score ≥ 15 or Child-Pugh-Turcotte Stage B or C
- •Known positivity for Human Immunodeficiency Virus (HIV) infection
- •Any subject who had major surgery within 8 weeks of Day 1, significant traumatic injury, or anticipation of need for major surgical procedure during the course of the study.
- •Weight reduction surgery within the past 3 years.
- •Any subject with current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening will be excluded.
- •Any subject with concurrent infection including diagnoses of fever of unknown origin (FUO) (subjects must be afebrile at the start of therapy).
- •Any history of malignancy, except for the following adequately-treated non metastatic basal cell skin cancer; any other type of skin cancer, except melanoma, that has been adequately treated and has not recurred for at least 1 year prior to enrollment; and adequately treated in situ cervical cancer that has not recurred for at least 1 year prior to enrollment.
- •Participation in an investigational new drug (IND) trial in the 30 days before randomization
- •Clinically significant medical or psychiatric condition considered a high risk for participation in an investigational study.
- •Failure to give informed consent
- •Subjects with known allergies to the study drug or any of its excipients.
- •Is an employee or family member of the investigator or study site personnel.
- •Any subject who cannot undergo an MRI, e.g., due to certain metal or electronic device implants, as determined by the Principal Investigator.
研究组 & 干预措施
GR-MD-02
Active Comparator
Active
干预措施: GR-MD-02 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS)
时间窗: 16 weeks
Difference in baseline adjusted mean change in liver fibrosis of corrected T1 (cT1) mapping with LiverMultiScan (LMS). LiverMultiScan is CE marked as a class IIa medical device. Corrected T1 (cT1) is a Magnetic Resonance (MR) relaxation parameter/measure from the device.The measure cT1 can be compared across different Magnetic Resonance Imaging (MRI) systems and sites. It is an emerging biomarker for rapid quantification of hepatic fibro-inflammatory disease. In unhealthy tissue, such as in inflamed and fibrotic tissues, measures result in longer cT1-relaxation.
次要结局
- Baseline-adjusted Change in Liver Stiffness With MR-elastography (MRE)(16 weeks)
- Baseline-adjusted Change in Liver Stiffness by FibroScan®(16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Estudio clínico de fase II, doble ciego, explorador, de grupos paralelos y controlado con placebo para evaluar dos pautas posológicas de GSK2402968 para la eficacia, seguridad, tolerabilidad y farmacocinética en sujetos ambulatorios con distrofia muscular de DuchenneDistrofia muscular de DuchenneMedDRA version: 12.1Level: LLTClassification code 10013801Term: Duchenne muscular dystrophyEUCTR2010-018412-32-ESGlaxoSmithKline Research and Development LTD54
尚未招募
2 期
A Phase II, Double-Blind 2-arm study to investigate the effect on ventricular ectopy, safety, tolerability and pharmacokinetics of S48168 (ARM210) compared with Placebo in adults with Type 1 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT1)abnormal heart rhythm10007521arrhythmiaNL-OMON53588ARMGO Pharma Inc.15
进行中（未招募）
1 期
Study of Nivolumab in Combination with Ipilimumab compare to nivolumab in combination with Ipilimumab-Placebo in patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)MedDRA version: 20.0Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001645-64-CZBristol-Myers Squibb International Corporation675
进行中（未招募）
1 期
Study of Nivolumab in Combination with Ipilimumab compare to nivolumab in combination with Ipilimumab-Placebo in patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)MedDRA version: 21.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001645-64-BEBristol-Myers Squibb International Corporation675
进行中（未招募）
1 期
Study of Nivolumab in Combination with Ipilimumab compare to nivolumabin combination with Ipilimumab-Placebo in patients with Recurrent orMetastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(SCCHN)MedDRA version: 21.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001645-64-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO675